In the Headlines
March 18, 2025
Reg Attys Talk FTC Healthcare and Antitrust Under Ferguson
Law360
Antitrust attorney David Kully was quoted in a Law360 article discussing changes in healthcare antitrust enforcement under the new Federal Trade Commission (FTC) leadership. Though there may be adjustments, particularly concerning private equity, Mr. Kully said he anticipates that antitrust scrutiny in the healthcare sector will remain robust. He emphasized that the current administration is expected to maintain rigorous oversight of transactions that could raise concerns about competition.
"Maybe there were certain peculiarities of the Biden enforcement that won't continue to be pursued. But to the extent that there are transactions involving healthcare companies that are potentially anticompetitive, I think that they're going to get the same attention as they would have in the past administration," he said.
READ: Reg Attys Talk FTC Healthcare and Antitrust Under Ferguson (Subscription required)
"Maybe there were certain peculiarities of the Biden enforcement that won't continue to be pursued. But to the extent that there are transactions involving healthcare companies that are potentially anticompetitive, I think that they're going to get the same attention as they would have in the past administration," he said.
READ: Reg Attys Talk FTC Healthcare and Antitrust Under Ferguson (Subscription required)